ArticleBioengineering & translational medicine2025
Multimodal near-infrared molecular imaging of ex vivo endometrial carcinoma via CD47-based targeted tracer.
Article in Bioengineering & translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Compact dual-channel visible-light fluorescence endoscope for real-time molecular imaging: system design and validation in ectopic pregnancy tissue.Biomedical optics express · 2026Article
- Multimodal near-infrared molecular imaging of ex vivo endometrial carcinoma via CD47-based targeted tracer.Bioengineering & translational medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The detection and complete eradication of early-stage small tumors during hysteroscopy remains a significant clinical challenge in preserving fertility for young women with endometrial cancer (EC). The purpose of this study is to verify the feasibility of CD47 as an optical molecular imaging (OMI) target for human EC and to achieve precise localization and identification in hysteroscopic surgery. The results demonstrated that CD47 was overexpressed in EC through bioinformatics, immunohistochemistry, and qRT-PCR. In EC cell lines, CD47-targeted near-infrared photoimmunotherapy (NIR-PIT) induced cytotoxicity in a light dose-dependent manner. Laser confocal microscopy revealed that CD47 intervention significantly increased the phagocytic effect of macrophages on EC cells. In the mice model of partial tumor resection mediated by CD47-targeted OMI, compared to group A (immune therapy alone), group C (NIR-PIT treatment) mice showed a reduced tumor recurrence rate after NIR-PIT intervention. However, the difference did not reach statistical significance. We then evaluated the effect of CD47-targeted NIR-PIT maintenance therapy on tumor recurrence in mice. The results indicated that, compared to untreated animals, the tumor growth rate was slower in the NIR-PIT group using CD47-Alexa Fluor 790 (CD47-AF790), allowing for more sustained tumor control. The freshly isolated whole uterus specimens from EC patients were co-incubated with CD47-AF790, and a significantly enhanced contrast of NIR visible images of tumor tissue was observed, demonstrating high sensitivity and specificity (tumor-to-background ratio >5.05). Finally, under fluorescence microscopy, specific fluorescent signals are observed on tumor cells. In conclusion, accurate localization and excision of EC can be accomplished by employing CD47 optical molecular contrast agents with OMI technology. This method shows potential as a viable and promising approach for the precise diagnosis of EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.